Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer

MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping non-small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches.